A functional variant of vascular endothelial growth factor is associated with severe ischemic complications in giant cell arteritis

Journal of Rheumatology

Volumn 32, Issue 9, 2005, Pages 1737-1741

  Rueda, Blanca ^a,b   Lopez Nevot, Miguel A ^c   Lopez Diaz, Maria J ^d   Garcia Porrua, Carlos ^d   Martín, Javier ^a,b   Gonzalez Gay, Miguel A ^d  

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^b CSIC   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^d HOSPITAL XERAL CALDE   (Spain)

Author keywords

Gene polymorphisms; Giant cell (temporal) arteritis; Temporal artery biopsy; Vascular endothelial growth factor; Vascular ischemic complications; VEGF

Indexed keywords

VASCULOTROPIN;

AGED; ANGIOGENESIS; ARTICLE; DNA POLYMORPHISM; FEMALE; GENE FUNCTION; GENOTYPE; GIANT CELL ARTERITIS; HUMAN; ISCHEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SYSTEMIC VASCULITIS;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COHORT STUDIES; CONFIDENCE INTERVALS; FEMALE; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; ISCHEMIA; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, GENETIC; PROBABILITY; PROGNOSIS; REFERENCE VALUES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TEMPORAL ARTERIES; TEMPORAL ARTERITIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 24944519879     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Gonzalez-Gay MA, Garcia-Porrua C. Epidemiology of the vasculitides. Rheum Dis Clin North Am 2001;27:729-49.
2. Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002;347:261-71.
3. Levine SM, Hellmann DB. Giant cell arteritis. Curr Opin Rheumatol 2002;14:3-10.
4. Weyand CM, Goronzy JJ. The Dunlop-Dottridge Lecture: The pathogenesis of giant cell arteritis. J Rheumatol 2000;27:517-22.
5. Weyand CM, Goronzy JJ. Arterial wall injury in giant cell arteritis. Arthritis Rheum 1999;42:844-53.
6. Cid MC, Hernandez-Rodriguez J, Esteban MJ, et al. Tissue and serum angiogenic activity is associated with low prevalence of ischemic complications in patients with giant-cell arteritis. Circulation 2002;106:1664-71.
7. Kaiser M, Younge B, Bjornsson J, Goronzy JJ, Weyand CM. Formation of new vasa vasorum in vasculitis. Production of angiogenic cytokines by multinucleated giant cells. Am J Pathol 1999;155:765-74.
8. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9-22.
9. Marumo T, Schini-Kerth VB, Busse R. Vascular endothelial growth factor activates nuclear factor-kappa B and induces monocyte chemoattractant protein-1 in bovine retinal endothelial cells. Diabetes 1999;48:1131-7.
10. Kim I, Moon SO, Kim SH, Kim HJ, Koh YS, Koh GY. Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. J Biol Chem 2001;276:7614-20.
11. Cid MC, Cebrian M, Font C, et al. Cell adhesion molecules in the development of inflammatory infiltrates in giant cell arteritis: inflammation-induced angiogenesis as the preferential site of leukocyte-endothelial cell interactions. Arthritis Rheum 2000;43:184-94.
12. Meliconi R, Pulsatelli L, Dolzani P, et al. Vascular endothelial growth factor production in polymyalgia rheumatica. Arthritis Rheum 2000;43:2472-80.
13. Brogan IJ, Khan N, Isaac K, Hutchinson JA, Pravica V, Hutchinson IV. Novel polymorphisms in the promoter and 5′ UTR regions of the human vascular endothelial growth factor gene. Hum Immunol 1999;60:1245-9.
14. Awata T, Inoue K, Kurihara S, et al. A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 2002;51:1635-9.
15. Lambrechts D, Storkebaum E, Morimoto M, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 2003;34:383-94.
16. Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990;33:1122-8.
17. Chuang TY, Hunder GG, Ilstrup DM, Kurland LT. Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Ann Intern Med 1982;97:672-80.
18. Gonzalez-Gay MA. Giant cell arteritis and polymyalgia rheumatica: two different but often overlapping conditions. Semin Arthritis Rheum 2004;33:289-93.
19. Gonzalez-Gay MA, Garcia-Porrua C, Amor-Dorado JC, Llorca J. Fever in biopsy-proven giant cell arteritis: Clinical implications in a defined population. Arthritis Rheum 2004;551:652-5.
20. Gonzalez-Gay MA, Pineiro A, Gomez-Gigirey A, et al. Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis. Medicine Baltimore 2004;83:335-41.
21. Carmeliet P, Jain R. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
22. Salvarani C, Boiardi L, Casali B, et al. Vascular endothelial growth factor gene polymorphisms in Behcet's disease. J Rheumatol 2004;31:1785-9.
23. Boiardi L, Casali B, Nicoli D, et al. Vascular endothelial growth factor gene polymorphisms in giant cell arteritis. J Rheumatol 2003;30:2160-4.
24. Gonzalez-Gay MA, Garcia-Porrua C, Rivas MJ, Rodriguez-Ledo P, Llorca J. Epidemiology of biopsy proven giant cell arteritis in northwestern Spain: trend over an 18 year period. Ann Rheum Dis 2001;60:367-71.
25. Salvarani C, Macchioni P, Zizzi F, et al. Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in northern Italy. Arthritis Rheum 1991;34:351-6.
26. Gonzalez-Gay MA, Amoli MM, Garcia-Porrua C, Ollier WE. Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica. Semin Arthritis Rheum 2003;33:38-48.
27. Dababneh A, Gonzalez-Gay MA, Garcia-Porrua C, Hajeer A, Thomson W, Ollier W. Giant cell arteritis and polymyalgia rheumatica can be differentiated by distinct patterns of HLA class II association. J Rheumatol 1998;25:2140-5.
28. Salvarani C, Boiardi L, Mantovani V, et al. HLA-DRB1, DQA1, and DQB1 alleles associated with giant cell arteritis in northern Italy. J Rheumatol 1999;26:2395-9.
29. Salvarani C, Casali B, Boiardi L, et al. Intercellular adhesion molecule 1 gene polymorphisms in polymyalgia rheumatica/giant cell arteritis: association with disease risk and severity. J Rheumatol 2000;27:1215-21.
30. Amoli MM, Shelley E, Mattey DL, et al. Lack of association between intercellular adhesion molecule-1 gene polymorphisms and giant cell arteritis. J Rheumatol 2001;28:1600-4.
31. Amoli MM, Garcia-Porrua C, Llorca J, Ollier WE, Gonzalez-Gay MA. Endothelial nitric oxide synthase haplotype associations in biopsy-proven giant cell arteritis. J Rheumatol 2003;30:2019-22.
32. Salvarani C, Casali B, Nicoli D, et al. Endothelial nitric oxide synthase gene polymorphisms in giant cell arteritis. Arthritis Rheum 2003;48:3219-23.
33. Wernick R, Davey M, Bonafede P. Familial giant cells arteritis: report of an HLA-typed sibling pair and a review of the literature. Clin Exp Rheumatol 1994;12:63-6.
34. Weyand CM, Hicok KC, Hunder GG, Goronzy JJ. The HLA-DRB1 locus as a genetic component in giant cell arteritis. Mapping of a disease-linked sequence motif to the antigen binding site of the HLA-DR molecule. J Clin Invest 1992;90:2355-61.